Nov. 8, 2010 (Atlanta) -- An experimental pill may help to reduce pain and swelling and improve physical function in people with rheumatoid arthritis, according to findings from a late-stage study of more than 600 patients.
There was also a signal that people given the new drug, tasocitinib, may be more likely to go into remission than people given placebo. However, that finding could have been due to chance, says study leader Roy Fleischmann, MD, of the University of Texas Southwestern Medical Center in Dallas.
The findings were presented at a news briefing here, held in advance of the Fleischmann's formal presentation at the American College of Rheumatology meeting.
Oral Pill May Offer Alternative to Injectables
The hope is that the new pill will offer patients an attractive alternative to the injectable agents that dominate the RA market, says Alan K. Matsumoto, MD, of Arthritis and Rheumatism Associates in Washington, D.C. He was not involved with the work.
"The fact that tasocitinib is given orally is extremely exciting," Matsumoto tells WebMD. "If approved, it will become the first new oral drug for rheumatoid arthritis since Arava was OK'd in the late 1990s," he says.
Tasocitinib belongs to a new class of oral drugs, known as JAK inhibitors, that inhibit immune system cells that are thought to cause inflammation.
Tasocitinib Appears to Improve Rheumatoid Arthritis Symptoms
In the study, 611 people with moderate to severe rheumatoid arthritis who had an inadequate response to at least one other drug were randomly assigned to one of two doses of tasocitinib or placebo.
Among the findings:
- A total of 66% of patients who received the higher dose of tasocitinib had at least a 20% improvement in disease activity and symptoms after three months of treatment, compared with 60% of those given the lower dose and 27% of those who received a placebo.
- Scores on a questionnaire that asks about dressing, arising, eating, walking, hygiene, reach, grip, and activities improved more than twice as much in people taking either dose of tasocitinib, compared with placebo.
But for the third primary study goal, remission according to the Disease Activity Score-28 (DAS-28) at three months, tasocitinib did not offer a substantial advantage at either dosage relative to placebo.
DAS-28 scores take into account such measures as the number of joints tender to the touch and the number of swollen joints. Using this measure, 10% of patients on the higher tasocitinib dosage, 6% on the lower dose, and 4% on placebo were in remission at three months. But the difference in remission rates did not reach what doctors call statistical significance, Fleischmann tells WebMD. He says he received consulting fees and research support from Pfizer, which makes the drug and funded the new study.
Tasocitinib: Safety Profile in Rheumatoid Arthritis
After three months, all patients in the placebo group were switched over to one of the two doses of tasocitinib for another three months; the patients who had been on tasocitinib stayed on their original doses.
Over the entire six-month period, 25 patients (4%) taking the new drug had serious adverse events, with six cases of serious infection.
In findings that muddied the water, however, there was also an increase in good HDL cholesterol levels in some patients on tasocitinib.
"As a clinician, I'm not sure what this means," Fleischmann says.
Inflammation can depress blood lipid levels, and anti-inflammatory treatments can cause them to rise, he says.
Says Matsumoto, "As with all drugs, we need long-term information on safety. But from both and effectiveness and safety view, tasocitinib looks to be very promising."
Tasocitinib is also being studied for the treatment of several other disorders, including psoriasis, Crohn's disease, and ulcerative colitis. No price has been set.
This study was presented at a medical conference. The findings should be considered preliminary as they have not yet undergone the "peer review" process, in which outside experts scrutinize the data prior to publication in a medical journal.